Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 3/20 | 0.49 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.49 |
| ▸ | CPT2 | P23786 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013274 | 0.80 | FABP4 (0.48) | FABP4HTR6KMT2APOLBMEN1 | |
| SCHEMBL2312698 | 0.72 | HTR6 (0.50) | FABP4HTR6KMT2APOLBMEN1 | |
| SCHEMBL3623289 | 0.71 | RECQL (0.50) | CPT1ACPT1BCPT2RECQLFABP4 | |
| SCHEMBL2001031 | 0.70 | PDE4A (0.47) | HTR6KMT2ALMNAPOLBPKM | |
| SCHEMBL2009634 | 0.69 | HTR6 (0.46) | FABP4HTR6KMT2APOLBPKM | |
| SCHEMBL2008376 | 0.69 | HTR6 (0.54) | FABP4HTR6KMT2APOLBMEN1 | |
| SCHEMBL3626255 | 0.67 | RECQL (0.48) | CPT1ACPT1BCPT2RECQLHTR6 | |
| SCHEMBL2003719 | 0.67 | HTR6 (0.47) | HTR6KMT2APOLBMEN1 | |
| Trifluoroacetic Acid SCHEMBL3615844 | 0.67 | CPT2 (0.45) | CPT1ACPT1BCPT2RECQLFABP4 | |
| SCHEMBL3618370 | 0.66 | MCOLN3 (0.44) | CPT1ACPT1BCPT2RECQLFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200980-B9 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-12-28 | — | — | EP | claimed |
| EP-2200980-B1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-08-03 | — | — | EP | claimed |
| US-7964627-B2 | Amino arylsulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | claimed |
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-26 | — | — | US | claimed |
| US-7964627-B2 | Amino arylsulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR1A | CPT1A 2998/4885CPT1B 1114/4885CPT2 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.